HIV-1 is known to show a high degree of genetic diversity, which may have major implications for disease pathogenesis and prevention. If every divergent isolate represented a distinct serotype, then effective vaccination might be impossible. However, using a sensitive new plaque-forming assay for HIV-1, we have found that most infected patients make neutralizing antibodies, predominantly to a group-specific epitope shared among three highly divergent isolates. This epitope persists among divergent isolates and rarely mutates, despite the rapid overall mutation rate of HIV-1, suggesting that it may participate in an essential viral function. These findings, plus the rarity of reinfections among these patients, suggest that HIV-1 may be more susceptible to a vaccine strategy based on a group-specific neutralizing epitope than was previously suspected.
Skip Nav Destination
Article navigation
1 November 1989
Article|
November 01 1989
Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.
I Berkower,
I Berkower
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
Search for other works by this author on:
G E Smith,
G E Smith
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
Search for other works by this author on:
C Giri,
C Giri
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
Search for other works by this author on:
D Murphy
D Murphy
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
Search for other works by this author on:
I Berkower
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
G E Smith
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
C Giri
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
D Murphy
Division of Biochemistry and Biophysics, Food and Drug Administration, Bethesda, Maryland 20892.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1989) 170 (5): 1681–1695.
Citation
I Berkower, G E Smith, C Giri, D Murphy; Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.. J Exp Med 1 November 1989; 170 (5): 1681–1695. doi: https://doi.org/10.1084/jem.170.5.1681
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement